Close
ACHEMA MIDDLE EAST 2026

Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes, India

Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics. The drug was discovered...

Halaven – Treatment of Metastatic Breast Cancer, Japan

Halaven is a non-taxane drug developed by Eisai Co. for the treatment of metastatic breast cancer. In March 2010, Eisai submitted a new drug...

UCB Biologics Pilot Plant, Braine-l’Alleud

Brussels-based biopharmaceutical company Union Chimique Belge (UCB) broke ground for a new biotechnology pilot facility in Belgium in June 2010. The facility, located at...

Vivalis R&D Facility

Vivalis opened a new R&D facility in Saint-Herblain, Nantes, France on 28 June 2010. The facility, located adjacent to its existing bio-production facility, has...

Roche Pharmaceutical Manufacturing Plant

Roche Mustahzarlari has completed the construction of their pharmaceutical facility at Gebze, close to Istanbul, Turkey. The new drugs manufacturing facility will make solid...

Quintiles Drug Research Unit

Quintiles, a US-based biopharmaceutical services company, inaugurated its new research facility in London on 8 March 2010. Known as the Quintiles drug research unit,...

Novo Nordisk Insulin Cartridge

Novo Nordisk is upgrading the insulin production plant at its facility in Chartres, Eure-et-Loir region, France. The Danish company is one of the largest...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...